STCube "Developing New Immune Checkpoint Inhibitor Innovative Drug"

[Asia Economy Reporter Hyungsoo Park] Immuno-oncology developer STCube announced on the 11th that it presented two research results on its core pipeline 'anti-BTN1A1 antibody (hSTC810)' at the 'American Association for Cancer Research (AACR) 2022 Annual Meeting.' STCube has completed patient enrollment for hSTC810 and plans to start dosing the first patient.

Dr. Seunghan Yoo, who oversees the research and development of hSTC810, said, "As a result of thorough preparation in preclinical studies, we were able to proceed relatively smoothly with the clinical phase 1 trial approval not only from the US FDA but also from the Korean Ministry of Food and Drug Safety."

He added, "hSTC810 is a new paradigm immune checkpoint inhibitor candidate following the development of existing PD-1 and PD-L1 therapeutics," and introduced it as "an innovative new drug expected to have efficacy as a monotherapy."

He said, "It can be an alternative for cancer patients who do not respond to PD-1 and PD-L1 therapies," and "multinational pharmaceutical companies have also shown interest, and meetings to discuss technology transfer and other matters are ongoing."

At AACR, toxicity and pharmacokinetic results for the initial dose determination, the first stage of clinical phase 1 for the innovative drug hSTC810, as well as the synergistic effects of combination therapy with hSTC810 and radiation therapy, were disclosed.

hSTC810 is an innovative new drug targeting BTN1A1, an immune therapy target discovered for the first time in the world by STCube. Because it is exclusively expressed compared to PD-L1, the target of existing immune checkpoint inhibitors, it can act as a completely different new immune checkpoint therapy from existing PD-1 and PD-L1 therapies.